Aptamers Binding to c-Met Inhibiting Tumor Cell Migration

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The human receptor tyrosine kinase c-Met is crucial for cellular processes.
• Dysregulation of c-Met is implicated in various human malignancies, making it a therapeutic target.
• Hepatocyte growth factor (HGF) activates c-Met; bivalent antibodies can also activate it, limiting their therapeutic use.

Purpose of the Study:

• To generate and characterize novel aptamers for c-Met inhibition.
• To evaluate the therapeutic potential of these aptamers in blocking c-Met activation and signaling.
• To compare aptamer-based inhibition with existing therapeutic strategies.

Main Methods:

• Systematic evolution of ligands by exponential enrichment (SELEX) was used to generate the RNA aptamer CLN64.
• Characterization of aptamer binding affinity and specificity to c-Met.
• Assessment of aptamer-induced inhibition of HGF-dependent c-Met activation, signaling, and cell migration.

Main Results:

• The RNA aptamer CLN64 and a DNA aptamer CLN3 demonstrated high specificity and affinity for c-Met.
• Both CLN64 and CLN3 effectively inhibited HGF-induced c-Met activation, downstream signaling, and cell migration.
• Unlike bivalent antibodies, these aptamers did not induce c-Met activation.
• CLN3 competed with HGF binding, while both aptamers bound overlapping epitopes.

Conclusions:

• CLN64 and CLN3 are potent inhibitors of c-Met signaling with therapeutic and diagnostic potential.
• These aptamers offer an advantage over bivalent molecules by not inducing receptor activation.
• The aptamers serve as valuable tools for studying c-Met activation and inhibition mechanisms.